Diazoxide‐associated pulmonary hypertension in a patient with noncompaction cardiomyopathy-Reference-Cited by-同舟云学术

Diazoxide‐associated pulmonary hypertension in a patient with noncompaction cardiomyopathy

Published:2021-01 Issue:1 Volume:11 Page:1-3
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Sullivan Rachel T.¹^ORCID,Tillman Kathryn A.¹,Kindel Steven J.¹,Handler Stephanie S.¹

Affiliation:

1. Medical College of WisconsinChildren’s Hospital of WisconsinMilwaukeeWIUSA

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/2045894020987117

Reference10 articles.

1. Multiplicity of effectors of the cardioprotective agent, diazoxide.;Coetzee WA.;Pharmacol Ther,2013

2. FDA Drug Safety Communication: FDA warns about a serious lung condition in infants and newborns treated with Proglycem (diazoxide) www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐drug‐safetycommunication‐fda‐warns‐about‐serious‐lung‐condition‐infants‐and‐newborns‐treated(2015 accessed 15 June2020).

3. A case of severe diazoxide toxicity.;Silvani P;Pediatr Anesth,2004

4. Diazoxide‐induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: recommendations from a multicentre study in the United Kingdom;Chen SC;Clin Endocrinol (Oxf),2019

5. Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide;Herrera A;J Clin Endocrinol Metab,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary hypertension associated with diazoxide: the SUR1 paradox;ERJ Open Research;2023-10-12

2. Congenital Hyperinsulinaemic Hypoglycaemia—A Review and Case Presentation;Journal of Clinical Medicine;2022-10-12

3. Diazoxide;Reactions Weekly;2021-03